Systemic treatment for psoriasis with concomitant psoriatic arthritis
Treatment of psoriatic arthritis with pharmacologic therapy is recommended using a treat-to-target strategy aimed at remission or, when remission is not achievable, low disease activity, with regular assessment and therapy adjustment [1]. Systemic agents that control both skin psoriasis and psoriatic arthritis are recommended based on the dominant disease manifestations and the patient’s treatment history [1], [2].
Treatment goals and monitoring strategy
Therapy should be aimed at achieving remission or low disease activity with structured disease activity assessment and appropriate adjustment of treatment [1]. Target selection should account for all clinically relevant disease manifestations, including musculoskeletal and extra-articular domains [3].
Medication selection algorithm for disease domains
Medication selection should be based on psoriatic arthritis manifestation patterns (peripheral arthritis, axial disease, enthesitis/dactylitis, and skin disease severity) [1], [2], [3].
- Peripheral arthritis and/or enthesitis/dactylitis
- Conventional synthetic DMARDs (csDMARDs) are used when clinically appropriate, including methotrexate and other csDMARD options referenced in guideline algorithms [1], [2].
-
Biologic DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs) are used when csDMARD response is inadequate or disease severity warrants escalation [1].
-
Axial (spine and/or sacroiliac) involvement
-
bDMARDs and tsDMARDs with efficacy in axial disease are selected according to guideline-recommended pathways [1].
-
Predominant moderate-to-severe skin disease with concomitant psoriatic arthritis
- Agents with efficacy in both skin and joints are prioritized within guideline pathways [1], [2].
Core pharmacologic options for concomitant skin and joint disease
The following systemic drug classes are included in guideline pharmacologic management pathways for psoriatic arthritis [1], [2].
- TNF inhibitors (including adalimumab, certolizumab pegol, etanercept, infliximab, golimumab) [1], [2]
- IL-17 inhibitors (including secukinumab, ixekizumab, brodalumab) [1]
- IL-12/23 and IL-23 inhibitors (including ustekinumab, guselkumab, risankizumab, tildrakizumab) [1], [2]
- PDE4 inhibitor (apremilast) as a systemic option in selected circumstances [2], [4]
- Janus kinase inhibitors (JAK inhibitors) in guideline-recommended pathways for psoriatic arthritis [1]
Monotherapy versus combination therapy
csDMARD therapy is used as an initial systemic strategy when appropriate for the dominant disease manifestations [1], [2].
Escalation from csDMARDs to biologic or targeted synthetic therapies is recommended when treatment targets are not achieved adequately [1].
Initiation thresholds and indications for escalation
Escalation to biologic or targeted synthetic therapies is recommended when disease activity remains above target despite appropriate initial therapy or when disease severity supports earlier escalation per guideline algorithms [1].
When moderate-to-severe psoriasis with concomitant psoriatic arthritis is present and biologic treatments are not appropriate, apremilast is specifically suggested in German psoriasis guidance adapted from EuroGuiDerm [4].
Common pitfalls to avoid
Systemic therapy should not be managed solely around skin symptoms when psoriatic arthritis is present, because treatment decisions should consider all manifestations and targets in a multidomain approach [3].
Systemic glucocorticoids should not be used as standard psoriatic arthritis therapy; limited use during flares is addressed as a cautionary exception in psoriasis guidance adapted from EuroGuiDerm [4].
Practical targets and desired outcomes by guideline strategy
Achievement of remission or low disease activity is the treatment objective [1].
Clinical assessment and regular therapy adjustment are required to reach and sustain the chosen target [1], [3].
Key guidance for agent choice in combined psoriasis–PsA
For patients with concomitant psoriasis and psoriatic arthritis, selection of systemic therapy should prioritize agents that address both skin and joint manifestations within guideline pathways [1], [2].
In patients with moderate-to-severe psoriasis and concomitant psoriatic arthritis in whom biologic treatments are not appropriate, apremilast is suggested as the primarily considered systemic option after inadequate response to at least one csDMARD in German guidance adapted from EuroGuiDerm [4].